Audit: QRS - Fenugreek for Health & Longevity
Audit conducted on 22/09/2026 17:10 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 86 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All benefit/risk tier labels are the ER’s own section headings; protocol doses, time-to-effect values, gate items, all 12 biomarkers and all 7 qualitative markers are traceable to ER lines 347–378, 400–424, 455, 487–510. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | ER-cautious targets carried verbatim, e.g. marker_10_target “No established target for supplemented adults; track change from own baseline” (ER line 498) and marker_9_target (ER line 497). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Pregnancy remains an absolute Contraindication, not a caution; the testosterone claim is framed in at_a_glance as “the weakest part of the record”, matching ER line 534. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come only from the ER “Populations who should avoid Fenugreek” list; Key Interactions only from the ER interaction bullets; modifying factors are not surfaced as gates. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS carries no PMIDs, no NCT identifiers and no brand names (Testofen, Libifem, FenuSMART, Furocyst, Fenfuro are all absent); drug names in the gates are the ER’s own generic examples. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No author, institution, reviewer or manufacturer is named anywhere in the sheet. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, evidence-weighted register matches the ER; British spelling (“standardised”, “haemoglobin”, “oestradiol”, “dysmenorrhoea”) is preserved throughout. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Concrete doses, targets and time horizons are given without hedging or alarm, enabling action. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is stated as noun phrases and observed facts, not as orders to a patient. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No “should”, “must”, or imperative instruction in the QRS’s own voice; the cadence cell describes the monitoring pattern rather than prescribing it. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Protocol and Monitoring cells present the regimens and ranges used in trials rather than recommending them. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronoun appears anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are expanded where the ER expands them: “HbA1c (glycated haemoglobin)”, “ALT and AST (transaminases)”, “Child-Pugh Class B or C liver impairment (moderate to severe cirrhosis)”. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every gate, benefit and risk item is stripped to its key fact; mechanisms, magnitudes, citations and mitigations from the ER are all removed. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no “you”, “your”, “we”, “our” or “us” in the document. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Functional-optimal ranges (fasting glucose 75–85 mg/dL, HbA1c 4.8–5.3%, ALT/AST < 20/25 U/L) are pitched at an optimising reader, not at conventional lab cut-offs. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | The sheet presents twice-daily gram-level dosing, a 12-marker baseline panel and several-times-weekly capillary glucose checks without softening for convenience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Twelve interaction classes and a twelve-marker panel presuppose a reader prepared to act on detail. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | at_a_glance closes with “Effects are largest when starting values are already disturbed”, which is precisely the caveat that matters for an already-optimised reader (ER line 532). |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “Longevity” appears in the title and header topic; “anti-aging” appears nowhere in the file. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | No consumer-grade route-of-administration or adverse-event wording; the sheet uses “with meals”, “in two doses”, “allergic reactions”, “hypoglycaemia”. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All headings byte-identical to [qrs_template] (lines 437, 474, 516, 536, 542, 553, 572, 576–578, 603 of the template). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 38 template variable names present; the repeating marker_#* set is expanded to marker_1..marker_12 and qualitative_item# to qualitative_item_1..7. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The non-variable spans website=”evidence_review”, website=”audit” and website=”full_review” are unchanged; head, CSS and footer are byte-identical to the template. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section feeding the QRS is empty — all four benefit tiers, all four risk tiers, the contraindication list, the interaction list and the monitoring table are populated in the ER. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | action_1_label “Whole-seed metabolic protocol”, action_2_label “Standardised extract protocol” and action_3_label “Best time of day” match the ER bold labels at lines 402, 404 and 410 verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Benefit and risk items reuse the ER’s own sub-section headings; monitoring marker names reuse the ER table’s Biomarker column verbatim. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Character scan confirms no emoji or symbol characters; the ER’s 🟩/🟥/🟨 tier markers and ⚠️ Conflicted flags were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | The one-page A4 print stylesheet is intact and unmodified; no page-break or second-page structure was added, and every section was condensed to key facts within the completeness constraints imposed by items 9.2, 12.2, 13.2, 14.2 and 15.2. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14; it is the first element after the doctype on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” on line 3 and closing “—” on line 13; the preceding title text on line 2 is permitted. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in the header, footer or body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All nine values trimmed; only duration: “00:02” is quoted, which is required because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: fenugreek_2026-0909-0246_Opus_ER.md, matching the ER frontmatter filename at ER line 17. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.9.22, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0922-1703, correctly formatted. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version with no trailing qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: fenugreek_2026-0909-0246_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified: no leading or trailing whitespace on any of the nine lines; quoting used only where YAML requires it. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Fenugreek for Health & Longevity - Quick Reference Sheet”, matching canonical_topic at ER line 8 with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Fenugreek for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 09/22/2026, correctly derived from qrs_creation_date 2026-0922-1703. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”, matching the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header carries only the title and the template subline; the ER’s “Also known as” line was correctly not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens “Fenugreek is a bitter food legume sold as a culinary spice and as standardised seed extracts” — kind and use given before any evidence verdict. |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses ER Conclusion lines 532–534 and 538: metabolic effects, women’s symptom relief, the weak testosterone claim, and the baseline-dependence caveat. |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | 67 words. |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Legume/spice/extract framing from ER lines 37–39; metabolic list from line 532; women’s symptoms from line 532; testosterone weakness from line 534; baseline dependence from line 532. |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; uses “blood sugar”, “blood fats”, “upper blood pressure number”, “a smaller waist” and “period-pain symptoms” in place of clinical classifications. |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial name, year, author or sample size appears. |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric effect estimate, confidence interval or percentage appears. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All six items map to the ER “Populations who should avoid Fenugreek” list at ER lines 373–378. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All six ER avoid-list entries are present, none added and none dropped. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Six discrete <li> elements inside the stop_items span, lines 574–585. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | ER rationale correctly stripped, e.g. “Children under 18, in whom no efficacy data exist and allergic sensitisation is most common” reduced to “Children under 18”; no dash-trailing clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “all trimesters, and the two weeks before an expected delivery date”, “within 14 days”, “(ribociclib, palbociclib)” and “Child-Pugh Class B or C … (moderate to severe cirrhosis)” all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | The ER uses no ranking notation in this list; the CDK4/6 parenthetical is already a plain comma-separated list. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER identifies six such populations, and the section is correspondingly populated rather than empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty — six contraindications are listed. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All twelve items map one-to-one to the ER interaction bullets at ER lines 347–369. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All twelve ER interaction bullets carried; none duplicates an entry on the avoid-list. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Twelve discrete <li> elements inside the caution_items span, lines 593–612. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER severity label, mechanism sentence and “Mitigation:” clause was stripped; only the drug-class name and its example list remain. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All eight ER example-drug parentheticals are preserved intact, e.g. “(berberine, cinnamon extract, gymnema, bitter melon, chromium)” and “(warfarin, apixaban, rivaroxaban)”. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | The ER uses no ranking notation in these bullets; every parenthetical is already a plain comma-separated list. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER identifies twelve interaction classes, and the section is correspondingly populated rather than empty. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty — twelve key interactions are listed. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells map to the ER Therapeutic Protocol bullets at ER lines 402, 404 and 410. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The two dosing regimens (whole seed, standardised extract) plus timing are the three implementable decisions; the remaining ER bullets are background, provenance or pharmacokinetics. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three or more distinct actionable aspects and all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | “10 g/day” / “5 g of defatted seed powder twice daily with meals” (ER line 402), “500–1,000 mg/day” / “Saponin-standardised seed or husk extract in two doses” (ER line 404), “With meals” / carbohydrate-meal and 30–60 minute pre-training detail (ER line 410). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Post-meal glucose, fasting glucose and lipids, and menopausal symptom scores — drawn from ER line 455, with HbA1c and the hormonal endpoints folded into the sub-lines so all five ER horizons are represented. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered glycaemic control, blood lipids, menopausal relief — the ER’s own High-tier ordering at ER lines 159, 165 and 177. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies five distinct time-to-effect aspects and all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | “Immediate”, “4–8 weeks” with the “HbA1c requires 8–12 weeks” sub, and “6 weeks” with the “Hormonal endpoints took 8–12 weeks in trials” sub all match ER line 455. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information at line 455, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All fifteen items are the ER Expected Benefits sub-section headings from ER lines 159–247. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four populated: 4 high, 2 medium, 6 low, 3 speculative — matching the ER tier counts exactly. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Every ER “Magnitude:” figure, mechanism sentence and citation is stripped; items are reduced to the heading phrase alone. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content appears in any benefit item. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers contain items in the ER, so no span needed hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All ten items are the ER Potential Risks & Side Effects sub-section headings from ER lines 269–329. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four populated: 1 high, 2 medium, 5 low, 2 speculative — matching the ER tier counts exactly. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | The ER’s sotolone, IgE, case-report and 66.3% co-sensitisation detail is all stripped; items are reduced to the heading phrase alone. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content appears in any risk item. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers contain items in the ER, so no span needed hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | The table reproduces the ER Monitoring Protocol & Defining Success biomarker table at ER lines 487–500. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All twelve ER biomarkers present with names, optimal ranges and rationales carried verbatim; the ER’s Context/Notes column was correctly dropped for the one-page format. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 817–820 condense ER lines 483 and 485: baseline panel, several-times-weekly capillary glucose for four weeks, repeat panel at 12 weeks, then every 6–12 months, plus the transaminase addition. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All seven items come from the ER qualitative-marker list at ER lines 504–510. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All seven ER qualitative markers present and carried verbatim, none added or dropped. |
Issues 22/09/2026 17:10
Pass rate 100.00%. No issues found.